Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer · 2024-06 · 12 (6) · e008686
DOI: 10.1136/jitc-2023-008686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.06.2024. Verfasst von Chengpei Zhu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Gastrointestinal Microbiome, Liver Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, CAMS Innovation Fund for Medical Sciences, CSCO-MSD Cancer Research Fund.
Abstract (Originalsprache)
Background
The association between gut bacteria and the response to immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) has been studied; however, multi-kingdom gut microbiome alterations and interactions in ICI-treated HCC cohorts are not fully understood.
Methods
From November 2018 to April 2022, patients receiving ICI treatment for advanced HCC were prospectively enrolled. Herein, we investigated the multi-kingdom microbiota characterization of the gut microbiome, mycobiome, and metabolome using metagenomic, ITS2, and metabolomic data sets of 80 patients with ICI-treated HCC.
Results
Our findings demonstrated that bacteria and metabolites differed significantly between the durable clinical benefit (DCB) and non-durable clinical benefit (NDB) groups, whereas the differences were smaller for fungi. The overall diversity of bacteria and fungi before treatment was higher in the DCB group than in the NDB group, and the difference in diversity began to change with the use of immunotherapy after 6–8 weeks. We also explored the alterations of gut microbes in the DCB and NDB groups, established 18 bacterial species models as predictive biomarkers for predicting whether immunotherapy is of sustained benefit (area under the curve=75.63%), and screened two species of bacteria ( Actinomyces_sp_ICM47 , and Senegalimassilia_anaerobia ) and one metabolite (galanthaminone) as prognostic biomarkers for predicting survival in patients with HCC treated with ICI.
Conclusions
In this study, the status and characterization of the multi-kingdom microbiota, including gut bacteria, fungi, and their metabolites, were described by multiomics sequencing for the first time in patients with HCC treated with ICI. Our findings demonstrate the potential of bacterial taxa as predictive biomarkers of ICI clinical efficacy, and bacteria and their metabolites as prognostic biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing,…
- Department of General Surgery Center, Beijing Youan Hospital, Clinical Center for Liver Cancer, Capital Medical University, Beijing, China.
- Microbiome Research Center, Moon (Guangzhou) Biotech Ltd, Guangzhou, China.
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China.
- Microbiome Research Center, Moon (Guangzhou) Biotech Ltd, Guangzhou, China zhaoht@pumch.cn jxz@moonbio.com Wanghp@pumch.cn yangxiaobo67@pumch.cn.
ORCID-Profile: Haitao Zhao
Förderung
- National High Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Sciences
- CSCO-MSD Cancer Research Fund
- CSCO-hengrui Cancer Research Fund
- National Ten-thousand Talent Program
Zitieren
APA
Zhu, C., Zhang, C., Wang, S., Xun, Z., Zhang, D., Lan, Z., Zhang, L., Chao, J., Liang, Y., Pu, Z., Ning, C., Sang, X., Yang, X., Wang, H., Jiang, X., & Zhao, H. (2024). Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer, 12(6), e008686. https://doi.org/10.1136/jitc-2023-008686
Vancouver
Zhu C, Zhang C, Wang S, Xun Z, Zhang D, Lan Z, et al. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2024;12(6):e008686. doi:10.1136/jitc-2023-008686
BibTeX
@article{Zhu2024,
author = {Zhu, Chengpei and Zhang, Chenchen and Wang, Shanshan and Xun, Ziyu and Zhang, Dongya and Lan, Zhou and Zhang, Longhao and Chao, Jiashuo and Liang, Yajun and Pu, Zilun and Ning, Cong and Sang, Xinting and Yang, Xiaobo and Wang, Hanping and Jiang, Xianzhi and Zhao, Haitao},
title = {Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {6},
pages = {e008686},
doi = {10.1136/jitc-2023-008686}
}
EUVIMED